Patents by Inventor Fangting Wu

Fangting Wu has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11293018
    Abstract: Chromatin looping is key to gene regulation, yet no broadly applicable methods to selectively modify chromatin loops have been described. Disclosed herein is an engineered method for chromatin loop reorganization using CRISPR-dCas9 (CLOuD9) to selectively and reversibly establish chromatin loops. Disclosed herein is the power of this technology to selectively modulate gene expression at targeted loci.
    Type: Grant
    Filed: June 8, 2018
    Date of Patent: April 5, 2022
    Assignees: THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY, SYSTEM BIOSCIENCES INC.
    Inventors: Kevin Chun-Kai Wang, Stefanie Morgan, Fangting Wu, Chiao-Chain Huang
  • Patent number: 10202619
    Abstract: The invention relates to engineered CRISPR/Cas9 systems for genomic modification in mammalian cells. The present specification describes the design and testing of a polynucleotide encoding the Streptococcus pyogenes (S. pyogenes) Cas9 protein, where the nucleotide sequence has been optimized for expression in mammalian cells. The specification also describes all-in-one systems for RNA-guided genome engineering in mammalian cells, including human cells.
    Type: Grant
    Filed: October 5, 2015
    Date of Patent: February 12, 2019
    Assignee: SYSTEM BIOSCIENCES, LLC
    Inventor: Fangting Wu
  • Publication number: 20180355344
    Abstract: Chromatin looping is key to gene regulation, yet no broadly applicable methods to selectively modify chromatin loops have been described. Disclosed herein is an engineered method for chromatin loop reorganization using CRISPR-dCas9 (CLOuD9) to selectively and reversibly establish chromatin loops. Disclosed herein is the power of this technology to selectively modulate gene expression at targeted loci.
    Type: Application
    Filed: June 8, 2018
    Publication date: December 13, 2018
    Inventors: Kevin Chun-Kai Wang, Stefanie Morgan, Fangting Wu, Chiao-Chain Huang
  • Patent number: 9738908
    Abstract: The invention relates to engineered CRISPR/Cas9 systems for genomic modification and regulation of gene expression in mammalian cells. The specification describes the design and validation of polynucleotides encoding the Streptococcus pyogenes (S. pyogenes) Cas9 gene and protein and variants of that protein, where the nucleotide sequence has been optimized for expression in mammalian cells, and also modified by fused sequences that enhance various aspects of the CRISPR/Cas system. The specification also describes systems for RNA-guided genome engineering and gene regulation in mammalian cells, including human cells.
    Type: Grant
    Filed: March 17, 2014
    Date of Patent: August 22, 2017
    Assignee: System Biosciences, LLC
    Inventor: Fangting Wu
  • Publication number: 20160138046
    Abstract: The invention relates to engineered CRISPR/Cas9 systems for genomic modification in mammalian cells. The present specification describes the design and testing of a polynucleotide encoding the Streptococcus pyogenes (S. pyogenes) Cas9 protein, where the nucleotide sequence has been optimized for expression in mammalian cells. The specification also describes all-in-one systems for RNA-guided genome engineering in mammalian cells, including human cells.
    Type: Application
    Filed: October 5, 2015
    Publication date: May 19, 2016
    Inventor: Fangting WU
  • Patent number: 9234213
    Abstract: The invention relates to engineered CRISPR/Cas9 systems for genomic modification in mammalian cells. The present specification describes the design and testing of a polynucleotide encoding the Streptococcus pyogenes (S. pyogenes) Cas9 protein, where the nucleotide sequence has been optimized for expression in mammalian cells. The specification also describes all-in-one systems for RNA-guided genome engineering in mammalian cells, including human cells.
    Type: Grant
    Filed: March 14, 2014
    Date of Patent: January 12, 2016
    Assignee: System Biosciences, LLC
    Inventor: Fangting Wu
  • Patent number: 9005888
    Abstract: The invention relates to compositions and methods for isolation of microvesicles produced by mammalian cells. These microvesicles, known as extracellular microvesicles or circulating microvesicles, are isolated from sample materials such as body fluids, or from cell culture media that has been used to culture and maintain mammalian cells in vitro. The isolation of microvesicles as described herein results in purification and concentration of the microvesicles. The invention also provides related methods for producing blood serum and/or blood plasma that is free of detectable microvesicles, largely depleted of microvesicles, or has reduced concentration of microvesicles compared to the blood serum or blood plasma starting material (collectively termed “microvesicle-depleted”).
    Type: Grant
    Filed: June 14, 2013
    Date of Patent: April 14, 2015
    Assignee: System Biosciences, LLC
    Inventors: Travis John Antes, Kevin Kwei, Fangting Wu
  • Patent number: 8852926
    Abstract: There is provided an expression cassette comprising a 3?-UTR cDNA library fragment, mammalian cells transfected with the expression cassette, and kits comprising the same. Furthermore, methods for identifying target genes for microRNAs are provided that utilize the expression cassette hereof.
    Type: Grant
    Filed: October 24, 2008
    Date of Patent: October 7, 2014
    Assignee: Board of Trustees of Southern Illinois University
    Inventors: Yin-Yuan Mo, Fangting Wu
  • Publication number: 20140273037
    Abstract: The invention relates to engineered CRISPR/Cas9 systems for genomic modification in mammalian cells. The present specification describes the design and testing of a polynucleotide encoding the Streptococcus pyogenes (S. pyogenes) Cas9 protein, where the nucleotide sequence has been optimized for expression in mammalian cells. The specification also describes all-in-one systems for RNA-guided genome engineering in mammalian cells, including human cells.
    Type: Application
    Filed: March 14, 2014
    Publication date: September 18, 2014
    Applicant: System Biosciences, LLC
    Inventor: Fangting Wu
  • Publication number: 20140273226
    Abstract: The invention relates to engineered CRISPR/Cas9 systems for genomic modification and regulation of gene expression in mammalian cells. The specification describes the design and validation of polynucleotides encoding the Streptococcus pyogenes (S. pyogenes) Cas9 gene and protein and variants of that protein, where the nucleotide sequence has been optimized for expression in mammalian cells, and also modified by fused sequences that enhance various aspects of the CRISPR/Cas system. The specification also describes systems for RNA-guided genome engineering and gene regulation in mammalian cells, including human cells.
    Type: Application
    Filed: March 17, 2014
    Publication date: September 18, 2014
    Applicant: System Biosciences, LLC
    Inventor: Fangting Wu
  • Publication number: 20090137421
    Abstract: There is provided an expression cassette comprising a 3?-UTR cDNA library fragment, mammalian cells transfected with the expression cassette, and kits comprising the same. Furthermore, methods for identifying target genes for microRNAs are provided that utilize the expression cassette hereof.
    Type: Application
    Filed: October 24, 2008
    Publication date: May 28, 2009
    Applicant: BOARD OF TRUSTEES OF SOUTHERN ILLINOIS UNIVERSITY
    Inventors: Yin-Yuan Mo, Fangting Wu